The Cleveland Clinic Foundation

Other

University of Massachusetts

Synthezyme, LLC

New York University

Polytechnic University

Dow Corning Corporation

Btg International Limited

Dna Twopointo Inc.

Polytechnic University of Nyu

Richard A Gross

Anthony Calabro

Aniq B Darr

Stephen P McCarthy

Kiyotaka Fukamachi

Vishal Shah

Keiji Kamohara

Ajay Kumar

Graham Swift

David L Kaplan

Fang Deng

Thomas Howard Lane

Kurt Friedrich Brandstadt

Wenhua Lu

Anthony Miniaci

Hilel Lewis

Marshall Strome

Zhaozong Jiang

Bhanu Kalra

Lee Akst

Daniel Alam

James Chan

David Haynes

Daniel P Knott

Mark H Schofield

Alex Melamud

Jeremy S Minshull

Jin Woo Lee

Jon Edward Ness

Arthur Winston Martin

Gustavo F Doncel

Michael K Banbury

Rajesh Kumar

Peter A Zahos

Alfred L Allen

Frantisek Nerud

Yixin Yang

Datta Madamwars

Walter G Yeomans

Rachna Dave

Manoj Genesh

Xianhai Chen

Michael S Reeve

Thavasi Rengathavasi

John E Kemnitzer

Devang T Shah

Amanda Koh

Kirpal Bisht

Wenguang Ma

Yifeng Peng

A method for the development of a library of modified sophorolipids using a wide-range of chemical and enzyme catalyst tools to identify modified sophorolipids that can be used in pure form, as mixtures with other modified sophorolipids, as mixtures with natural sophorolipids, as mixtures with modified and natural sophorolipids, and as mixtures with other compounds known by one skilled in the art for use in the dispersion, solubilization or emulsification of various oil types and nutraceuticals, and modified sophorolipids for use in dispersion, solubilization or emulsification processes.

Modified sophorolipids as oil solubilizing agents

A composition of matter comprising sophorolipids as antimicrobial agents, antifungal agents, biopesticides, for uses as drugs to treat HIV, septic shock, cancer, asthma, dermatological conditions, as spermicidal agents, as anti-inflammatory drugs, as ingredients in cosmetics and building blocks for monomers and polymers and self-assembled templates for further chemical elaboration.

Sophorolipid analog compositions

A method for producing sophorolipids having protein inducer and/or repressor activities having the steps of synthesizing the sophorolipid by fermentation ofin a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids and then utilizing the natural mixture as a protein inducing agent, utilizing the natural mixture as a protein repressing agent, and/or utilizing the natural mixture as a combined protein induction/repressor agent. An application of the sophorolipid compound produced according to the method as a microbial media component.

Sophorolipids as protein inducers and inhibitors in fermentation medium

17-L-[(2'-O-&#x3b2;-D-glucopyranosyl-&#x3b2;-D-glucopyranosyl)-oxy]-cis-9-octa-decenoate, lactonic and open ring 17-L-[(2&#x2032;-O-&#x3b2;-D-glucopyranosyl-&#x3b2;-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, methyl 17-L-[(2&#x2032;-O-&#x3b2;-D-glucopyranosyl-&#x3b2;-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, ethyl 17-L-[(2&#x2032;-O-&#x3b2;-D-glucopyranosyl-&#x3b2;-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, hexyl 17-L-[(2&#x2032;-O-&#x3b2;-D-glucopyranosyl-&#x3b2;-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, ethyl 17-L-[(2&#x2032;-O-&#x3b2;-D-glucopyranosyl-&#x3b2;-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6&#x2033;-acetate and ethyl 17-L-[(2&#x2032;-O-&#x3b2;-D-glucopyranosyl-&#x3b2;-D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6&#x2032;,6&#x2033;-diacetate sophorolipids and uses thereof as antifungal agents.

Method for neutralizing fungi using sophorolipids and antifungal sophorolipids for use therein

A method for neutralizing or inactivating a virus, and neutralizing or inactivating HIV using sophorolipids having antiviral properties produced by synthesizing the sophorolipid by fermentation ofin a fermentation media to form a natural mixture of lactonic sophorolipids compounds and non-lactonic sophorolipids compounds and utilizing the natural mixture as an antiviral agent, and/or separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction and utilizing the lactonic fraction and/or the non-lactonic fraction as an antiviral agent, and sophorolipid compounds for use as antiviral agents.

Virucidal properties of various forms of sophorolipids

A biodegradable material, capable of carrying a bioactive agent, comprising a polymer matrix and an enzyme capable of degrading the polymer matrix to enable the release of the bioactive agent.

Embedded enzymes in polymers to regulate their degradation rate

A dihydroxyphenyl cross-linked macromolecular network is provided that is useful in artificial tissue and tissue engineering applications, particularly to provide a synthetic macromolecular network for a wide variety of tissue types. In particular, artificial or synthetic cartilage, vocal cord material, vitreous material, soft tissue material and mitral valve material are described. In an embodiment, the network is composed of tyramine-substituted and cross-linked hyaluronan molecules, wherein cross-linking is achieved via peroxidase-mediated dityramine-linkages that can be performed in vivo. The dityramine bonds provide a stable, coherent hyaluronan-based hydrogel with desired physical properties.

Hydroxyphenyl cross-linked macromolecular network and applications thereof

A substantially purehost cell for the production of a &#x3b1;-carboxyl-&#x3c9;-hydroxy fatty acid having a carbon chain length in the range from C6 to C22, a &#x3b1;,&#x3c9;-dicarboxylic fatty acid having a carbon chain length in the range from C6 to C22, or mixtures thereof, is provided. Thehost cell is characterized by a first genetic modification class and a second genetic modification class. The first genetic modification class comprises one or more genetic modifications that disrupt the peroxisomal &#x3b2;-oxidation pathway. The second genetic modification class comprises one or more genetic modifications that collectively or individually disrupt at least one gene selected from the group consisting of a CYP52A type cytochrome P450, a fatty alcohol oxidase, and an alcohol dehydrogenase.

[object Object]

A method and process for the preparation of ricinoleic acid analogs and oligomers and polymers containing such ricinoleic acid analogs.

Method for preparing long-chain hydroxyacids, diacids and oligomers and polymers thereof

A synthetic nucleus pulposus is provided that is useful in treatment of degenerative disc disease, augmentation of a degenerate disc, and alleviation of back pain. In an embodiment the synthetic nucleus pulposus comprises hyaluronan macromolecules that have been cross-linked via dihydroxyphenyl linkages. The synthetic nucleus pulposus restores or improves the water-retention capability of the disc. A method of treating an intervertebral disc with the cross-linked hyaluronan macromolecules is also provided. A method of regenerative therapy to address loss of cells of nucleus pulposus of an intervertebral disc based on treatment with the cross-linked hyaluronan macromolecules and mesenchymal stem cells is also provided.

An enzymatic process for preparing aliphatic polycarbonates via terpolymerization or transesterification using a dialkyl carbonate, an aliphatic diester, and an aliphatic diol or triol reactant. A catalyst having an enzyme capable of catalyzing an ester hydrolysis reaction in an aqueous environment is subsequently added to the reaction mixture. Next, polymerization of the reaction proceeds for an allotted time at a temperature&#x2266;100&#xb0; C. Finally, the copolymer is isolated from an the catalyst via filtration.

Enzyme-catalyzed polycarbonate and polycarbonate ester synthesis

A method and composition for the prophylaxis or treatment of humans or animals for septic shock and sepsis using a mixture of sophorolipids.

Treatment and prophylaxis of sepsis and septic shock

Growing community of inventors

Plainview, NY, United States of America

Richard A Gross